+ Watch SIAL
on My Watchlist
The Company develops, manufactures, purchases and distributes the high quality biochemicals and organic chemicals.
Overvalued S&P 500 member with tippy charts and heavy selling by insiders. I wouldn't pay more than $46.00 for it.
Sigma Aldrich started to acquire fairly prominent biotech companies starting in 2008. Since then they have seen an increase in net income near 50% and an increase in stock price around 90%. Based on past company acquisitions in the right areas of scientific research and the increasing health care trends, I think SIAL will outperform.
Sigma-Aldrich is a staple supplier for biomedical and chemical research, an industry which has been underfunded for several years; that scene is improving, meaning more demand for SIAL products.
HIGH DIVIDENDS AS BONDS PLUMMET
When you open the chemical storage cabinets in any labortory, most containers have one thing in common - "SIGMA-ALDRICH"...When scientist and researcher has chemical in mind that needed to be ordered, SIAL is one of them (another is Fisher Scientific, TMO, I also give a UP thrumb)...SIAL won't grow as big as other big names (GOOG, AMZN, you name it), but it is one of the big names in the scientific community. More importantly, they are so efficient that other small player can't compete with them.
Number 1 in their class.
Good company, growing cash flow - solid products and place in the ScienceIndustrialComplex. *****
million $ port.
Manufactures advanced biochemicals and equipment and sells them in 40 counties. PE of 19. Why?
Average 10 year ROE of 20%. Industry leader.
SIAL is a pretty safe bet. With a beta of 0.76, it is less risky than the market. SIALs financials are much stronger than the industry average, and they have a smart mangement team. Sigma-Aldrich also has a really low debt level. SIAL is a steady performer, and its share prices have moved up at a pretty steady rate. And, though this stock may not have spectacular short-term gains, it is a safe, long-term play. Since it divested its metals division and decided to focus on research chemicals, it has outperformed steadily for the last 6-7 years.
Very underpriced for a high quality health chemical research stock. Their pipeline of antibodies to link to all 22,000 known human proteins will be vital for future research in all fields of medicine.
bio 101 we all need high tech bio materials
Extra $10B for the NIH in the stimulus package; some will end up in SIAL's pockets.
Triple weekly bottom at 35, 14 weeks trading at the 40 level showing zero momentum. Trading between the 9 and 18 weekly moving average. Buy at 40, stop at 38
Steady dividend, reasonable P/E, retaining it's value well through the downturn, I think they have positive prospects going forward. Recent drop is them being the baby in the bath, I reckon.
lots of insider selling seems to be going on, including the head of R&D. Maybe just taking advantage of the stock being over $60 but too much for my tastes.
part of the mattchenzo 50, picked from the s&p500 on fundamentals, almost sure to outperform!
When a stock gets positive press, it usually does pretty well. On 4/24/08, the Street.com named SIAL one of 5 top midcaps. The company gets the positive buzz for good reason. The company grew 14.9% in Q1 FY08 versus Q1 FY07. Net income increased by 12.8%. In addition, the management has raised their earning forecast for full FY08 by $0.05 per share to $2.57 to $2.67, up 9.8% and 14.1% over FY07. The company is highly efficient, is financially solvent, has improved income and has shown outstanding growth.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions